Učitavanje...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Spremljeno u:
Glavni autor: | |
---|---|
Format: | Artigo |
Jezik: | Russo |
Izdano: |
ABV-press
2021-09-01
|
Serija: | Opuholi Ženskoj Reproduktivnoj Sistemy |
Teme: | |
Online pristup: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|